Active, not recruitingNot applicableNCT05024695
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Studying NON RARE IN EUROPE: Primary adult open-angle glaucoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- iSTAR Medical
- Principal Investigator
- Sabine GlibertiSTAR Medical
- Intervention
- MINIject™ Implant(device)
- Enrollment
- 975 enrolled
- Eligibility
- 46 years · All sexes
- Timeline
- 2021 – 2029
Study locations (30)
- Arizona Advanced Eye Research Institute, Glendale, Arizona, United States
- Vold Vision, Fayetteville, Arkansas, United States
- Beverly Hills Institute of Ophthalmology, Beverly Hills, California, United States
- Reeve Woods Eye Center, Chico, California, United States
- Sacramento Eye Consultants, A Medical Corporation, Sacramento, California, United States
- Grand Junction Eye Care, Grand Junction, Colorado, United States
- Eye Associates of Fort Myers, Fort Myers, Florida, United States
- Intermountain Eye Center, Eagle, Idaho, United States
- Illinois Eye Center, Peoria, Illinois, United States
- Virdi Eye Clinic, Rock Island, Illinois, United States
- Stiles Eyecare Excellene and Glaucoma Institute, Overland Park, Kansas, United States
- LA Eye and Laser, Alexandria, Louisiana, United States
- Minnesota Eye Consultants, Bloomington, Minnesota, United States
- Eye Consultants PC, Omaha, Nebraska, United States
- Center for Sight Las Vegas, Las Vegas, Nevada, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05024695 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07354516Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionQlaris Bio, Inc.
- RECRUITINGNCT07303257Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical OptionsHospices Civils de Lyon
- RECRUITINGPHASE1, PHASE2NCT06921317GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle GlaucomaIVIEW Therapeutics Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT07082816Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionAlcon Research
- ACTIVE NOT RECRUITINGPHASE2NCT06030193Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)Qlaris Bio, Inc.
- RECRUITINGNANCT06682962Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle GlaucomaOkuvision GmbH
- RECRUITINGPHASE4NCT06848946Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneGlaukos Corporation
- RECRUITINGNCT06691555Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) ShuntDavinci LTD
See all trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma →